The page is the record's research on the issuer — no analyst, no rating, no view. # GYRE THERAPEUTICS, INC. (NASDAQ: GYRE) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing The issuer is GYRE THERAPEUTICS, INC., listed on NASDAQ under ticker GYRE. ISIN US4037831033; LEI 549300XPJNYCRWY2KU30. Security type is Corporate; segment is not on the record. Sector is 2834 Pharmaceutical Preparations; jurisdiction is United States, Delaware. Listing status: listed, not halted. ## The disclosure read The record holds 68 filings in the twelve months to 2026-11-08, across 42 filing days. The median gap between filing days is 4 days. The latest filing is dated 2026-11-06, two days before the record date, and is of type results. NASDAQ's median is 52 filings, a median cadence gap of 6.0 days and a median latency of 5.0 days. Sector 2834 Pharmaceutical Preparations has a median of 63.0 filings, a median cadence gap of 6.0 days and a median latency of 4.0 days. The issuer's 68 filings are above the NASDAQ median and above the sector median of 63.0. Filings by type: directors' dealings 30, corporate news 10, results 9, regulatory filings 9, AGM/EGM 5, director changes 2, prospectuses 2, takeover 1. ## Auditor The auditor of record is not on the record, because the latest annual report cover carries no dei:AuditorName tag. Its location is not on the record. The record holds no auditor changes. ## Events and halts The record holds no listing, delisting or name change lines. Domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. Segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. Halt flag: listed, not halted. ## Orderability The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. Rule version: acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, chapter as of 2026-11-04. ## Coverage No research houses were found on the issuer's investor-relations pages read. The count is 0. ## Open research No openly published research notes were found on the record. The count is 0. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth Sealed years holding the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. ## Sources 8 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin) - https://data.sec.gov/submissions/CIK0001124105.json (identity.jurisdiction) - https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei) - https://mcp.us-cm-kg.ai/events/NASDAQ/GYRE (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://mcp.us-cm-kg.ai/record/NASDAQ/GYRE (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NASDAQ/GYRE · public-record only · the same page signed and receipted: get_research at https://mcp.getresearch.ai/mcp